Cutaneous T-cell Lymphoma

The magnificent, multitasking @DrKrinaPatel joins a non-MM session to teach us all about allo anti-CD70 CART. Look at this response in a patient with stage IVA2 transformed mycosis fungoides! #DAVABermudaHeme https://t.co/Nzs1eKSTqc (@KE_Gallaway)

So, it could be cd8+ aggressive primary cutaneous tcl, could be a gamma/delta tcl, could still be an alcl, need to perform cd30, or could be a peripheral tcl. (@et565)

During the Hidradenitis Suppurativa Workgroup update, @_AprilArmstrong moderated reports on Itch, Cutaneous T-Cell Lymphoma, and #Geriatric Dermatology. Contact @DanielButlerMD to join a new task force, Aging and Geriatric Evaluation in #Dermatology (AGED)! #IDEOM2023 (4/9) (@Dermoutcomes)

Gabapentin is a good option. In CTCL paradigm could also consider mirtazapine, aprepitant or naltrexone. cc @BradHaverkos @NehaMehtaShahMD (@majorajay)

Mycosis fungoides and syphilis? (@professorneill)

Quick question for #lymsm folks who treat cutaneous lymphomas: what patient-reported itch instrument are you using in your clinics? #CTCL cc @BradHaverkos @NehaMehtaShahMD (@majorajay)

Le SOC ACTUEL DANS CTCL ET PLUS !!! (@rickallandu34)

Some sort of cutaneous T-cell lymphoma? (@jacobmshaner)

#17ICML P Porcu shows data of #lacutamab, an anti-KIR3DL2 in #MycosisFungoides #lymsm (@DrRaulCordoba)

$iph $ipha #Lacutamab#MycosisFungoides #ICML2023 (@krmhrr13)

Dr. @BradHaverkos published an @icmlugano #17ICML abstract of outcomes of mogamulizumab combined with other therapies in CTCL. cc @mana1981 @StevenBairMD @majorajay @mcolton_2 #lymsm https://t.co/glCKEIgTox (@CULymphoma)

How do you confirm that it is mycosis fungoides (@MahaSakr19)

AHCT vs nonAHCT in CTCL is in favour of AHCT as a result of a French study (@mbeksac56)

Blood smears @ASH_hematology 🧵Heme boards 🩸Malignant Hematopoietic Neoplasms🩸 #mmsm #lymsm #leusm #bmtsm 1⃣5⃣ Sezary syndrome 🩸Mature T-cell Leukemia 🩸Sezary cell 👇 CD3+/CD4+ 🩸erythroderma, generalized lymphadenopathy (@HadidiSamer)

Oncology and Dermatology Board Review A patient presents with newly diagnosed mycosis fungoides with patches and plaques over 30% of their body. Imaging reveals no systemic disease. Flow with no blood involvement. Biopsy CD30+ tumor cells. The most appropriate therapy? (@AaronGoodman33)

In cutaneous T-cell lymphoma, a high combined PD1, PD-L1 and ICOS checkpoint marker score is associated with advanced-stage disease and lower overall survival:. Read more in this months' @BrJDermatol: https://t.co/EQBAN5zr6e (@BJDEditor)

I had a similar patient with sezary syndrome, used mogalizumab to get to CR pre alloSCT. Doing ok 3 yrs post transplant. Can also use Brentuximab if cd30 positive. (@PallawiTorkaMD)

Mycosis Fungoides Pearls CD3+CD4+CD7−CD26− CD8+ = hypopigmented MF Patch = Flat Plaque = Raised scale Tumor = >1cm = T3 = Advanced stage (IIb) Rare types: Pagetoid reticulosis = unilesional on leg, super indolent Granulomatous slack skin = slow development of sagging skin (@AaronGoodman33)

Mycosis Fungoides Pearls CD3+CD4+CD7−CD26− CD8+ = hypopigmented MF Patch = Flat Plaque = Raised scale Tumor = >1cm = T3 = Advanced stage (IIb) Rare subtypes: Pagetoid reticulosis = unilesional on leg, indolent Granulomatous slack skin = slow development of sagging skin (@AaronGoodman33)

CD4+ Directed #CART trial open for T-cell NHL (PTCL_NOS; angioimmunoblastic; CTCL allowed) @MedicalCollege. Please DM or email if we can facilitate treatment or our #lymphoma team @timfenske @niravshahmd #lymsm https://t.co/3a7vzK14VV (@MediHumdani)

Excellent presentation on CD30/CCR4 CAR-T for cHL/CTCL by my colleague @NatalieGroverMD -Heavily pretreated cHL, N=11 -ORR 84% -CR 61% -PFS cHL only - Not reached -some durable remissions (CR>3yrs!) @anne_beaven @SeroBMT1 (@cedittus)

#ASH21 CD30-Directed CAR-T Cells Co-Expressing CCR4 in R/R cHL & CD30+ Cutaneous TCL. ✔️n=13 (6 DL1, 3 DL2, 3 DL3, 1 DL4) ✔️Median 5.5 LOT ✔️6/8 HL CR ✔️No dose limiting toxicities ✔️Responses seen at the lowest dose level @NatalieGroverMD @CARTTherapy (@uroosaibrahim)

CD30 expression in lymphoma 100% of time Hodgkin lymphoma Systemic anaplastic large cell lymphoma (Both ALK-/+) Primary cutaneous ALCL Lymphomatoid papulosis Sometimes DLBCL PTCL, NOS Angioimmunoblastic Mycosis fungoides (more often with large cell transformation) (@AaronGoodman33)

PD-1 loss and T-cell exhaustion in CTCL tumoral T cells https://t.co/XGqInq8g2m (@BloodJournal)

Heme and dermatology aficionados don’t disappoint me. 50 yo with new diagnosis mycosis fungoides with 25% body surface area involvement with patch/plaque stage disease. PET and blood negative. Biopsy with atypical CD7- T cells that strongly express CD30. Best treatment rec? (@AaronGoodman33)

But it's CD4+...Looks more like a Sezary or mycosis fungoides to me... (@TheRealDSrini)

US FDA Grants Priority Review for Brentuximab Vedotion in treatment of CTCL @AACR @ASCO @SeattleGenetics #lymphoma https://t.co/jYZtuBHdDm (@ADCReview)

Seattle Genetics Submits Supplemental Biologics License Application for Brentuximab Vedotin in CTCL https://t.co/s1y7Llb4aW @ASCO #lymphoma (@OncoZine)

Seattle Genetics Submits Supplemental Biologics License Application for Brentuximab Vedotin in CTCL https://t.co/ovZVVM2ZDe @ASCO #lymphoma (@ADCReview)